

The
Patent
Office

PCT/GB 99/01413



5

INVESTOR IN PEOPLE

09 / 67 4892

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP9 1RH

GB99/1413

REC'D 15 JUN 1999


WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subject the company to certain additional company law rules.



**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)


Signed

Andrew Gersey

Dated

26 May 1999

THIS PAGE BLANK (USPTO)



9809666.2

07 MAY 98 £355.00 + 5 D00192
P01/7700 25.00 - 9809666.2

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form))

- 6 MAY 1998

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

P.74383 JCI

2. Patent application number

(The Patent Office will fill in this part)

3. Full name, address and postcode of the or of each applicant (underline all surnames)

ISIS INNOVATION LIMITED
2 South Parks Road
Oxford
OX1 3UB
United Kingdom

Patents ADP number (if you know it)

C 359 9 856 4001.

If the applicant is a corporate body, give the country/state of its incorporation

UNITED KINGDOM

4. Title of the invention

MODIFIED VIRUSES

5. Name of your agent (if you have one)

J A KEMP & CO

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

14 SOUTH SQUARE
GRAY'S INN
LONDON WC1R 5LX

Patents ADP number (if you know it)

26001.

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer "Yes" if:

YES

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body:

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	0
Description	35
Claim(s)	4
Abstract	1
Drawing(s)	5

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(*please specify*)

11. I/We request the grant of a patent on the basis of this application

Signature

J. C. Irvine

6 MAY 1998

12. Name and daytime telephone number of person to contact in the United Kingdom J.C. IRVINE
0171 405 3292

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered "Yes" Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

MODIFIED VIRUSES

The present invention relates to modified viruses, in particular attenuated influenza viruses which may be employed as an influenza virus vaccine. Modified
5 viruses of the invention also include recombinant attenuated influenza viruses suitable for use as viral vectors for expression of heterologous sequences in target cells.

Influenza remains a constant worldwide threat to human health. While inactivated influenza virus vaccines have been available for many years, such vaccines provide only limited protection. Previous efforts to provide a safe, live attenuated
10 influenza vaccine have focussed primarily on cold-adapted influenza viruses. Thus, attenuated influenza viruses have previously been obtained by extensively passaging influenza virus at low temperatures. As a result of adaptation to growth at low temperature, influenza viruses which have lost their ability to replicate at higher temperatures (about 39°C) are obtained. The replication of such cold-adapted (CA)
15 viruses is only slightly restricted in the cooler upper respiratory tract, but highly restricted in the warmer lower respiratory tract, the major site of disease-associated pathology. Sequence comparisons between wild-type and CA influenza viruses have revealed both silent mutations and non-silent mutations leading to amino acid changes in the coding regions of several gene segments. Most amino acid changes were found
20 to be the result of point mutations. The genetic instability of point mutations, and the level of immunogenicity of CA influenza viruses, remain as perceived potential problems in use of CA influenza viruses as vaccines for worldwide general use.

Another approach to obtaining attenuated influenza viruses which has been investigated is the construction of chimeric influenza viruses in which a non-coding
25 region of an influenza virus genomic segment is substituted by a non-coding region from a genomic segment of an influenza virus of a different type. Such attenuated chimeric A/B influenza viruses are discussed, for example, in Muster et al., Proc. Natl. Acad. Sci. USA (1991) 88, 5177-5181, Luo et al., J. Virology (1992) 66, 4679-4685 and Bergmann and Muster, J. General Virology (1995) 76 3211-3215.

30 Three types of influenza virus are known designated as types A, B and C. Each of these types has many strains. The genome of an influenza virus is a segmented genome consisting of a number of negative sense RNAs (8 in the case of types A and B and 7 in the case of type C), which encode (in the case of type A) 10

polypeptides: the RNA-directed RNA polymerase proteins (PB1, PB2 and PA) and nucleoprotein (NP) which form the nucleocapsid, the matrix proteins (M1, M2), two surface glycoproteins which project from the lipoprotein envelope (hemagglutinin (HA) and neuraminidase (NA)) and the non-structural proteins NS1 and NS2. The majority of the genomic RNA segments are monocistronic. Thus, in the case of influenza virus of type A, 6 of the 8 genomic RNA segments are monocistronic and encode HA, NA, NP and the viral polymerase proteins, PB1, PB2 and PA.

During the replication cycle of an influenza virus, the viral genome (vRNA) is transcribed into mRNA and replicated into complementary RNA (cRNA) molecules, which in turn are used as templates for vRNA synthesis. These processes are known to be catalyzed by the viral polymerase complex consisting of three subunits formed by the PB1, PB2 and PA polypeptides. mRNA synthesis is initiated by capped RNA primers, which are cleaved from host cell mRNA by an endonuclease associated with the viral polymerase complex. The synthesis of mRNA is prematurely terminated at a run of uridines, in the case of an influenza A virus 16 or 17 nucleotides away from the 5' end of the vRNA template, and subsequently a poly(A) tail is added. On the other hand, cRNA synthesis is believed to be initiated in the absence of primer resulting in full-length precise copies of the vRNA segments. The nucleoprotein has been implicated as a switching factor, which acts as an antiterminator during cRNA synthesis.

Influenza vRNA segments may be prepared *in vitro* by transcription from plasmid DNA and mixed with viral polymerase proteins and nucleoprotein to form ribonucleoprotein complexes (RNPs) having all the components necessary for transcription and replication. Such RNPs can be incorporated into viable influenza virus particles in cell packaging systems, e.g. employing a helper virus.

The development of RNP reconstitution and transfection systems has permitted detailed characterization of the RNA signals in influenza A vRNAs involved in the regulation of transcription initiation, termination, and polyadenylation (4, 20-22, 25, 32, 34). All these signals are known to reside in the terminal sequences of vRNA segments (19). The 5' and 3' ends contain 13 and 12 conserved nucleotides respectively, which have the ability to form a partially double-stranded panhandle/RNA-fork or corkscrew structure (6, 7, 13). Initial *in vitro* transcription

studies with model RNA templates implied that vRNA and cRNA promoters were located exclusively in the 3' terminal sequences (25, 32) and that the panhandle had no apparent role in the initiation of transcription *in vitro*. However, detailed mutagenesis studies of the terminal sequences subsequently showed that the 5' end forms an
5 integral part of the promoter. These findings were based on binding experiments of the RNA polymerase to the putative promoter RNA (7, 33) and, more importantly, on *in vitro* transcription studies with mutant model template RNAs (7, 8, 28). In addition, activation of the viral polymerase-associated endonuclease requires interaction of the polymerase complex with the 5' as well as the 3' terminal sequences
10 of vRNA segments (11).

The postulated double-stranded region of the promoter of an influenza A vRNA segment is now recognised to consist of 5 to 8 base-pairs. The first 3 base-pairs, those formed by nucleotides 11' to 13' at the 5' end and nucleotides 10 to 12 at the 3' end, are strictly conserved among different vRNA segments of all influenza A
15 viruses. Sequencing studies have shown that the 3' and 5' non-coding terminal sequences of influenza B and C vRNA segments are also highly conserved and show partial inverted complementarity (36, 37). Consequently, it is believed that the capability of base-pairing of nucleotides of the non-coding regions to form a panhandle structure is important for proper functioning of all influenza vRNAs. The
20 term duplex region of an influenza vRNA segment as used hereinafter will be understood to refer to a region which may be formed by such base-pairing.

Kim et al. (14) have previously used a chloramphenicol acetyltransferase (CAT) reporter gene construct in which negative sense CAT RNA is flanked by the non-coding sequences of an influenza A virus NS gene to determine the effect of
25 mutations in the postulated duplex promoter region on CAT expression in Madin-Darby bovine kidney (MDBK) cells. Negative-sense CAT RNA constructs were incorporated into RNP complexes, which were then used to transfect monolayers of MDBK cells infected with a helper influenza virus and CAT activity assayed. Using this model system, single mutations of the conserved residues at positions 11 and 12
30 of the 3' terminus and at positions 12' and 13' of the 5' terminus of the CAT gene construct were found to abolish or virtually abolish CAT activity. The introduction of second complementary mutations into such constructs so as to restore the capability

for Watson-Crick base-pairing was found, however, to partially restore CAT activity. Thus, the constructs with the base-pair substitutions of U12-A13' for C12-G13' and A11-U12' for C11-G12' were found to express CAT at 31% and 22% respectively compared to the control construct with wild-type influenza A gene non-coding regions.

5 The same CAT reporter gene system was also used to investigate the effect of mutations of the U10-A11' base-pair. Single mutations, U10 to G10 and A11' to C11', significantly decreased CAT activity, but both mutants exhibited detectable activity. A combination of the two mutations to introduce a G10-C11' base-pair did not give improved CAT activity. It was therefore suggested that the properties of the base-pair at positions 10-11' might be different from those at positions 11-12' and 12-13'.

10 Such experiments merely test the effect of influenza vRNA duplex region mutations on the expression of a heterologous CAT reporter gene in cultured human cells. It is not possible to predict from such studies whether mutations which allow some CAT activity will, when incorporated into an influenza vRNA genomic fragment, permit rescue of that fragment into a viable virus. Equally, it is not possible to predict, even if such mutations give rise to viable virus, whether such viruses will be attenuated. Indeed, this is supported by the finding of the inventors that the base-pair substitution of C12-G13' by U12-A13' in the NA gene vRNA segment of an influenza A virus can be rescued into a viable influenza A virus which does not show significant attenuation on MDBK cells (see the examples).

20 In contrast, it has now been established that substitution of A for C and U for G at position 11-12' in the duplex region of the NA-specific vRNA of an influenza A virus does lead to attenuation on MDBK cells and also other cell types in culture. It has been shown that such attenuation arises from reduced polyadenylation of the NA-specific mRNA. Base-pair substitution in the duplex region of a vRNA segment is thus proposed as a new general strategy for achieving attenuation of influenza viruses. Such base-pair substitution can be selected by application of known rescue systems for incorporating genetically-engineered influenza vRNA segments into viable influenza viruses as further discussed below.

30 In one aspect, the present invention thus provides an attenuated influenza

virus carrying a genomic nucleic acid segment which comprises 5' and 3' non-coding regions providing a mutated duplex region of an influenza virus RNA genomic segment operably-linked to a protein coding sequence for an influenza viral protein or functional modification thereof, wherein the said duplex has at least one base-pair substitution such that expression of the said protein-coding sequence in cells infected by the said virus is reduced.

The term "cells" in this context may encompass human and/or animals cells *in vivo* normally infected by influenza viruses. For the purpose of selection of attenuated viruses of the invention, the same term will be understood to refer to cells of a single cell type or more than one type, e.g. cultured human or non-human animal cells of one or more than one type. They may be *in vivo* cells, e.g. cells of an animal model. Cultured cells which may prove useful in the selection of attenuated viruses of the invention *in vitro* include one or more of MDBK cells, Madin-Darby canine kidney (MDCK) cells and Vero (African green monkey kidney) cells.

While an attenuated virus of the invention may have a single base-pair substitution in the duplex non-coding region of a genomic segment, it will be appreciated that such a virus may have more than one such substitution, either on the same genomic segment or a different genomic segment. The duplex base-pair substitution(s) will desirably result in some, e.g. at least about one log, reduction in plaque titre compared to the parent wild-type virus on MDBK cells. The duplex base-pair substitution(s) will desirably provide an attenuated virus exhibiting some, e.g. at least about one log, more preferably at least about 3 to 4 log, reduction of plaque titre on MDCK cells and Vero cells compared to the parent wild-type virus. An attenuated virus of the invention may, for example, exhibit as much as about 5 log reduction of plaque titre compared to the parent wild-type virus on Vero cells arising from the vRNA non-coding region base substitutions. Such an attenuated virus is exemplified by influenza A/WSN/33 having an NA-specific vRNA segment incorporating the base-pair substitution A11-U12' for C-G at position 11-12' of the duplex region and additionally having the base-pair substitution G10-C11' for U10-A11' (mutant D1/2 referred to in the examples). Other influenza A viruses incorporating the same base-pair substitutions, either in the NA-specific vRNA segment or a vRNA segment encoding another influenza virus protein, also exemplify

the invention.

As indicated above, attenuated viruses of the invention also include influenza A/WSN/33 having the single base-pair substitution A11-U12' in the NA-specific vRNA segment (mutant D2 referred to in the examples) and other influenza A viruses having the same base-pair substitution in the NA-specific vRNA segment or another viral protein-encoding vRNA segment. Thus, in one embodiment the present invention provides an attenuated influenza virus of type A carrying a mutated influenza A virus genomic RNA segment having the mutation C to A at position 11 from the 3' terminus and the mutation G to U at position 12' from the 5' terminus, or functionally equivalent substitutions at the same positions, so as to provide an attenuating base-pair substitution in the non-coding duplex region. Additionally, in a further embodiment, the present invention provides such an attenuated virus of type A which in the same vRNA segment has the mutation U to G at position 10 from the 3' terminus and the mutation A to C at position 11' from the 5' terminus, or functionally equivalent substitutions at the same positions, so as to provide an additional base-pair substitution in the non-coding duplex region. Such a virus may be a wild-type virus which has been attenuated by introduction of one or more base-pair substitutions as above into the non-coding duplex region, or a recombinant attenuated virus carrying a heterologous coding sequence as further discussed below. Desirably, for example, the attenuating base-pair substitution(s) will be introduced into the genomic nucleic acid segment encoding NA or a functional modification of that surface glycoprotein.

Although the invention is further illustrated hereinafter with particular reference to influenza A/WSN/33, the invention is not confined to influenza viruses of the A-type. Functionally equivalent mutations to the D2 or D1/2 mutations in viruses of the B and C types may be analogously identified by reference to available sequence information and application of known rescue systems applicable to any genetically-engineered influenza vRNA segment suitable for providing the characteristic of attenuation to a complete influenza virus.

Thus, a further embodiment of the invention, is an influenza virus of type B carrying a mutated influenza B virus genomic RNA segment having an attenuating base-pair substitution in the non-coding duplex region at a functionally homologous position to the base-pair substitution in influenza A/WSN/33 designated above as D2.

The invention also extends to influenza viruses of type C carrying such a base-pair substitution in a mutated influenza C virus genomic RNA segment.

Brief Description of the Figures

5 Figure 1 is a representation of the conserved sequences of an influenza A virus vRNA in the panhandle/RNA-fork conformation (7, 13). Conserved base-pairs in the double-stranded region of the RNA-fork, involving both the 5' and 3' ends of the RNA segment, are boxed. Numbering of residues starts from the 3' end and from the 5' end. The 5' end numbers are distinguished by prime ('). Base-pairs in the
10 conserved double-stranded region of the modified NA-encoding vRNA of the transfectant viruses designated D1, D2, D3 and D1/2 in the examples are shown. Changed base-pairs are highlighted.

 Figure 2 shows growth curves of transfectant viruses on MDBK cells. Confluent cells in 35 mm dishes were infected with wild-type influenza A/WSN/33
15 (wild-type; WT) virus, and with the transfectant D1, D2, D3 or D1/2 viruses at a multiplicity of infection (m.o.i.) of 0.01. At the indicated time points, infectious particles present in the media were titrated by plaque assay in MDBK cells. The presented values are averages from duplicate experiments.

 Figure 3 shows the nucleotide sequence of the plasmid pT3NAM1 containing
20 the full-length cDNA of the NA gene of influenza A/WSN/33 (positions 2412-3820) flanked by a unique BbsI restriction site at one end (position 2404) and a bacteriophage T3 RNA polymerase promoter at the other end (positions 3821-3836) in the background of the pUC19 cloning vector between the EcoR1 (position 2398) and Hind III (position 3837) restriction sites (9). This plasmid was employed to
25 obtain the mutant versions of the NA-encoding vRNA of influenza A/WSN/33 present in the D1, D2, D3 and D1/2 viruses (see example 1).

 A nucleic acid segment of a virus of the invention incorporating an attenuating base-pair substitution as discussed above, and DNAs capable of transcription to
30 provide such a nucleic acid, also constitute additional aspects of the invention. A nucleic acid of the invention may preferably correspond to a mutated native influenza virus RNA genomic segment having an appropriate attenuating base-pair substitution

in the non-coding duplex region. Such an RNA may have additional modifications, for example, one or more additional nucleotides added at the 3' and/or 5' terminus or internally which do not destroy function. It may be a chimeric RNA.

5 A DNA capable of transcription *in vitro* to provide an RNA nucleic acid segment of the invention may be initially constructed in a plasmid by application of conventional techniques and isolated from that plasmid by restriction endonuclease digestion. As illustrated by plasmid pT3NAml referred to above, for this purpose a cDNA of a native influenza virus vRNA segment may be inserted into a plasmid flanked by an appropriate promoter and a restriction endonuclease site. The cDNA
10 may then be subjected to site-directed mutagenesis by, for example, PCR-directed mutagenesis employing appropriate mutagenic primers to provide a sequence encoding the desired mutated vRNA segment for transcription. Alternatively, a genomic nucleic acid segment of the invention may be synthesized.

For preparation of an attenuated virus of the invention, a genomic nucleic acid
15 segment having at least one attenuating base-pair substitution as defined above may be complexed *in vitro* with influenza viral polymerase proteins and nucleoprotein to form a RNP complex. Such RNP complexes, which constitute a still further aspect of the present invention, may be prepared in conventional manner as previously employed for incorporation of genetically-engineered influenza virus RNA genomic
20 segments into RNA complexes for viral rescue in cells (4, 5, 38). RNP complexes of the invention may be transfected into cultured cells, e.g. MDBK cells, MDCK cells or Vero cells, again using conventional techniques. Methods commonly employed for this purpose include DEAE-dextran transfection and electroporation (19, 39).

In yet another aspect, the present invention provides a method of preparing an
25 attenuated influenza virus of the invention which comprises providing in a host cell the genomic nucleic acid segments for said virus under conditions whereby said segments are packaged into a viral particle. For this purpose, the genomic nucleic acid segments may be provided in the host cell by plasmids. Alternatively, RNP complexes of the invention as hereinbefore described may be transfected into host
30 cells that have previously been infected with an influenza helper virus to complement the RNP complexes and enable selection of the desired attenuated viral particles. A number of helper virus-based cellular rescue systems for particular influenza virus

genes have previously been described. Such gene specific rescue systems are briefly summarized below.

Helper virus based influenza gene rescue systems

5

Helper based rescue systems have been reported allowing the genetic manipulation of influenza A vRNAs for NA and HA surface antigens, the non-structural proteins, NP, PB2 polymerase protein and the M proteins.

10 NA gene specific rescue system

The most commonly employed helper virus based influenza gene rescue system is limited to the NA of influenza A/WSN/33 virus (4). This method is based on the observation that only influenza viruses with an NA gene from influenza
15 A/WSN/33 are able to grow on MDBK cells in the absence of trypsin. In this rescue system, the helper virus is a reassortant containing seven gene segments from influenza A/WSN/33 and a NA gene from a virus other than influenza A/WSN/33. Generally A/WSN-HK, which has an NA gene from influenza A/HK/8/68, is used as the helper virus. In this system, the NA gene of influenza A/WSN/33 is transfected
20 into cells infected with the helper virus. The virus is then selected by growing on MDBK cells in the absence of exogenous proteases.

NA genes can also be rescued by using a NA-deficient mutant virus as a helper virus. Such a helper virus requires exogenous neuraminidase to grow in tissue culture. The NA-gene is transfected into cells infected with the helper virus. The
25 virus is then selected by growing on cells in the absence of neuraminidase (43).

NS gene specific rescue system

A temperature-sensitive influenza virus with a defect in the NS1 protein is
30 used as the helper virus of a NS gene specific rescue system. The NS gene segment carries two overlapping genes coding for the NS1 and NS2 proteins. This rescue system allows the rescue of a NS gene segment encoding an NS1 protein which has

activity at the non-permissive temperature. In this system, the NS gene segment which is to be rescued is transfected into cells infected with the temperature-sensitive virus. The virus with the transfected NS gene segment is selected by growing the virus at the non-permissive temperature as described by Enami et al. (40).

5

PB2 gene specific rescue system

A virus with an avian influenza A virus PB2 gene can be used as the helper virus in a PB2 gene specific rescue system. The avian influenza A virus PB2 gene restricts the replication of the helper virus in mammalian cells. Therefore, this rescue system can rescue a PB2 gene which allows replication of influenza virus in mammalian cells. The PB2 gene which is to be rescued is transfected into cells infected with the helper virus. The virus with the transfected PB2 gene is selected by growing the virus in mammalian cells. Subbarao et al. (41) have used such an avian influenza A virus PB2 gene based system to rescue the PB2 gene of wild-type influenza A/Ann Arbor/6/60 virus.

15

M gene specific rescue system

An amantidine-sensitive influenza virus carrying an M gene of influenza A/equine/Miami/1/63 virus can be used as a helper virus of an M gene specific rescue system. The rescue system allows the rescue of an M gene which confers amantidine resistance to a virus. In this system, the M gene which is to be rescued is transfected into cells infected with the helper virus. The virus with the transfected M gene is selected by growing the virus in the presence of amantidine. Castrucci and Kawaoka (42) have used such an amantidine-sensitive M gene based system to rescue the M gene of influenza A/PR/8/34 virus.

25

Antibody-based rescue systems

30

These systems depend on the binding or non-binding of the transfectant virus to a particular antibody (5, 52). Such antibody is a neutralising antibody which binds

to influenza virus and impairs its growth in tissue culture. The helper virus may, for example, carry a gene which encodes an influenza surface protein which displays the antibody epitope. This system can therefore be used to select for transfectant virus which does not carry such a gene, but which of course is viable. This type of rescue system thus allows the rescue of a gene encoding an influenza surface protein. The gene to be rescued is transfected into cells infected with the helper virus. The virus with the transfected gene is selected by growing the virus in the presence of the antibody. Such a system was used by Enami and Palese (5) to rescue a transfected synthetic HA segment.

NP gene specific rescue system

Li and coworkers (39) reported a reverse genetics system for the rescue of the influenza A virus nucleoprotein gene. In this system, a temperature-sensitive (ts) mutant ts56 is used as a helper virus. RNA complexes are reconstituted *in vivo* as described before (5) and they are electroporated into ts56 helper virus infected cells. Transfectant viruses with a rescued NP-encoding vRNA segment are selected at the non-permissive temperature by plaquing on MDBK cells.

Influenza B virus rescue system

Barclay and Palese (44) have additionally described the rescue of HA genes in an influenza B virus.

The preparation of an attenuated virus of the invention may alternatively be achieved using the expression vector-based influenza gene rescue strategy developed by Pleschka et al. (45). In contrast to the RNP transfection system referred to above, this eliminates the need for purification of the viral NP and polymerase proteins which is required for *in vitro* reconstitution of RNP complexes. Expression vectors are co-transfected into host cells which will provide the NP and P proteins and also a genomic segment of the invention incorporating an attenuating base-pair mutation. In this case, RNP complexes of the invention are formed intracellularly. The cells may

then be infected with an influenza helper virus as previously described to select for the required attenuated influenza virus .

An RNA complex of the invention may also be rescued in host cells into a viable attenuated virus by transfecting into the host cells additional complementing
5 RNA complexes thereby eliminating the need for a helper virus. This may be achieved in accordance with the general rescue strategy for influenza virus genes more recently described by Enami (46). This strategy involves purifying RNPs from an appropriate influenza virus and treating the RNPs *in vitro* with RNase H in the presence of a cDNA which hybridizes to the influenza virus gene to be rescued. In this way specific
10 digestion of that gene by the RNase H is achieved. The gene depleted RNPs are then co-transfected into cells with the RNP-complex containing the nucleic segment to provide the attenuating base-pair substitution. The cells are then overlaid with agar and transfectant attenuated viruses obtained by direct plaque formation. This strategy, unlike the above described helper virus-based gene rescue strategies, can be
15 applied to any influenza gene from any influenza virus. It can thus be applied to obtain an attenuated virus or gene of the invention of any influenza type.

Since reversion of a base-pair mutation requires two specific mutations, attenuated influenza viruses of the invention are expected to be highly stable (see example 12). Hence, such viruses may be particularly favoured for use as influenza
20 virus vaccines.

As indicated above, a virus of the invention may additionally contain a heterologous coding sequence capable of being expressed in target cells. Such a heterologous coding sequence may encode an antigenic polypeptide capable of stimulating an immune response (either an antibody response or a cell-mediated
25 immune response) to a pathogenic agent. Representative examples of such pathogenic agents are viruses, e.g. other influenza viruses or HIV, bacteria, fungi, parasites, eg. malarial parasites, and cancer cells.

Thus, in yet another aspect, the present invention provides a vaccine comprising a virus of the invention. Particularly preferred are such vaccines wherein
30 the attenuated influenza virus acts as a combined vaccinating agent against more than one pathogenic agent. Such vaccines may be formulated and administered in accordance with known methods for this purpose. Intranasal immunisation may, for

example, be preferred as illustrated by the immunisation studies with recombinant influenza viruses expressing an HIV-epitope reported by Muster et al. (49) and Ferko et al. (53). Booster immunisations may be given following an initial immunisation with a virus having the same functional characteristics, but of a different subtype or type.

Methods for incorporating heterologous coding sequences into an influenza virus have previously been described, for example, in Published International Application WO91/03552 (Palese et al.). The heterologous coding sequence may be on a genomic segment incorporating an attenuating base-pair substitution or on a different genomic segment. It may be carried by an additional nucleic acid segment also incorporating a gene for an influenza viral protein to provide selection pressure. It has previously been reported, for example, that an influenza virus can be constructed carrying at least 9 different vRNA segments (40).

Use of attenuated recombinant influenza viruses of the invention as vectors to express foreign antigens for vaccinating purposes is an attractive therapeutic strategy since:

- (i) Antibodies to the different subtypes show little cross-reactivity. One drawback with the use of a virus as a vaccine is that an immune response will be produced to the virus. It is often desired that one or more booster immunisations comprising the same antigen are given after the initial immunisation. However, the immune response to the virus reduces the effectiveness of subsequent immunisations with the same virus. Since antibodies to different influenza subtypes show little cross reactivity, subsequent immunisations with an influenza virus of a different subtype but which expresses the same antigen should overcome this effect.
- (ii) Influenza viruses have been shown to induce strong cellular and humoral responses.
- (iii) Influenza viruses have been shown to induce strong mucosal responses. Intranasal immunisation with influenza virus has been shown to induce long lasting responses in genital and intestinal mucosa.
- (iv) Influenza viruses are non-integrating and non-oncogenic.
- (v) As previously noted above, attenuated influenza viruses of the invention can

be anticipated to be attenuation stable.

For vaccinating purpose, a heterologous coding sequence may be provided in an attenuated virus of the invention encoding an antigen of a pathogenic agent or a modification thereof capable of stimulating an immune response. The heterologous coding sequence may be inserted into a viral gene to provide a fusion protein which retains the function of the parent viral protein. One site which has previously been found to tolerate insertions of foreign antigens (epitope grafting) is the antigenic B site of HA. Antigenic site B of that surface protein consists of an exposed loop structure located on top of the protein and is known to be highly immunogenic.

Manipulation of the HA gene of an influenza virus to insert a viral epitope in the HA protein B site has previously been reported (see again the studies of Muster et al. reported in 49 and the studies of Li et al. reported in 48). The same strategy has also previously been employed by Rodrigues et al. to express B-cell epitopes derived from a malaria parasite (50). Heterologous coding sequences for an antigenic polypeptide may also, for example, be preferably inserted into an influenza virus NA gene. Strategies for epitope grafting into influenza viral proteins have also previously been described, for example, in WO91/03552.

Epitope grafting of a foreign sequence into an influenza virus protein may result in a non-functional chimeric viral protein and make the rescue of a viable transfectant virus impossible. A different strategy for expressing foreign sequences by recombinant influenza viruses, which may be applied to attenuated viruses of the present invention, involves the engineering of gene segments containing an additional open reading frame. A recombinant genomic segment may be constructed which provides an internal ribosome entry site for a heterologous coding sequence. This approach has previously been used, for example by Garcia-Sastre et al., to obtain an influenza virus vRNA segment which encodes both a truncated form of gp41 of HIV and NA (9). Alternatively, a heterologous coding sequence may be fused in frame to a viral protein coding sequence to encode a chimeric polyprotein capable of autoproteolytic protease cleavage to give the viral protein and a desired second polypeptide, e.g. a viral antigen. This strategy has been shown by Percy et al. to be suitable for expressing non-influenza proteins up to 200 amino acids in length (51).

It will be appreciated that a recombinant attenuated virus of the invention may

be employed as a vehicle for expression of heterologous coding sequences in target cells for a variety of therapeutic purposes in addition to vaccination. Such a recombinant virus may, for example, have a genomic segment encoding any of the following:

- 5 - a cytokine such as an interferon or an interleukin,
- a toxin,
- a palliative capable of inhibiting a function of a pathogenic agent either directly or indirectly, e.g. a viral protease inhibitor
- an enzyme capable of converting a compound with little or no
- 10 cytotoxicity to a cytotoxic compound, e.g. a viral enzyme such as Herpes simplex thymidine kinase capable of phosphorylating purine and pyrimidine analogues to active toxic forms,
- an antisense sequence,
- a ribozyme.

15

A heterologous coding sequence in an attenuated recombinant virus of the invention may be under the control of a tissue-specific and/or event-specific promoter. A recombinant virus of the present invention may be employed for gene therapy.

20 A recombinant virus of the invention may be administered directly or used to infect cells *ex vivo* which are then administered to a patient.

25 Thus, in still further aspects, the present invention provides a pharmaceutical composition comprising a recombinant virus of the invention in combination with a pharmaceutically acceptable carrier or diluent for delivery of a heterologous coding sequence to target cells. It also provides *ex vivo* cells infected by a virus of the invention and such cells hosting a recombinant influenza virus of the invention formulated for administration with a pharmaceutically acceptable carrier or diluent.

30 Viruses of the invention may also find use as a helper virus to rescue genes which can substitute for the gene(s) affected by the attenuating mutation(s) to provide viruses showing increased growth on a selected cell type. For this purpose, an attenuated virus will preferably be chosen which exhibits at least about a 3-4 log, preferably at least about a 5 log, reduction in growth compared to the corresponding wild-type virus on one or more cell types. Thus, in yet another embodiment, the

present invention provides use of a virus of the invention as a helper virus to rescue an influenza virus genomic nucleic acid segment in cells, wherein viruses produced containing said segment are selected on the basis of increased growth compared with the helper virus on cells of a selected type. For example, an influenza A virus of the invention having an attenuating base-pair substitution in the non-coding duplex region of its NA-encoding vRNA may be usefully employed to rescue an NA-encoding vRNA or functional modification thereof derived from a second influenza A virus. A typical protocol for this purpose will comprise the steps of:

1. infecting cells with the helper virus,
2. transfection of an RNP complex containing the gene(s) to be rescued into the helper virus infected cells, and
3. selection of rescued viruses, either on the same cell type or a different cell type on which the helper virus shows increased attenuation.

The cell type in step 3 will be chosen such that only viruses which have acquired the transfected gene(s) are expected to grow to high titre.

For example, the D1/2 mutant version of influenza A/WSN/33 referred to above is particularly favoured as a helper virus for use to rescue NA genes originating from other influenza viruses of the A-type. In this case, MDBK cells may, for example, be initially infected with the D1/2 helper virus and Vero cells preferably used for selection of viruses carrying an NA gene containing vRNA without an attenuating mutation. The D2 mutant derived from influenza A/WSN/33 may similarly be employed.

Influenza A/WSN/33 is known to exhibit in mice neurovirulence associated with the surface antigen NA (54). For this reason, the attenuated modified versions of that virus referred to above are not regarded as suitable for direct vaccine use. However, by using, for example, the D1/2 mutant as a helper virus as above, NA vRNAs may be obtained for site-directed mutagenesis to construct alternative attenuated influenza A viruses according to the invention more suitable for therapeutic, e.g. vaccine, use.

The following examples illustrate the invention.

Example 1

Introduction of mutations into the duplex region of the NA-encoding vRNA of an influenza virus of type A

5 In order to produce NA-encoding viral genomic RNA with mutations in the 5' and 3' non-coding regions, plasmids were constructed which contained the corresponding cDNA with the desired mutations.

The starting plasmid for site-directed mutagenesis was pT3NA_m1 (see Figure 3) which, as previously noted above, contains the full length cDNA of the NA gene of influenza A/WSN/33 virus (positions 2412-3820) flanked by a unique BbsI restriction site at one end (position 2404) and a bacteriophage T3 RNA polymerase promoter at the other end (positions 3821-3836) in the background of the pUC19 cloning vector between the EcoRI (position 2398) and Hind III (position 3837) restriction sites (9).
10 Samples of influenza A/WSN/33 for preparation of the NA-encoding cDNA insert in plasmid pT3NA_m1 are obtainable, for example, from the W.H.O. Collaborating
15 Centre, Division of Virology, National Institute for Medical Research, London, U.K.

An alternative plasmid which may be employed to construct DNA templates for transcription of mutant NA-encoding vRNA segments of influenza A/WSN/33 is the pUC19-derived plasmid pT3NA_v, whose construction is described in WO91/03552 (Palese, P. et al.). Plasmid pT3NA_v also contains the full length cDNA
20 of the NA gene of influenza A/WSN/33 flanked by a promoter specifically recognised by bacteriophage T3 RNA polymerase and a restriction endonuclease cleavage site.

PCR products were made using pT3NA_m1 as a template and the following primers modified to provide mutations as specified in Fig. 1:

5'-CGGAATTCTGAAGACGCAGCAAAAGCAGGAGTTTAAATGAATCC-3'

25 (primer 1) and 5'-

CCAAGCTTATTAACCCTCACTAAAAGTAGAAACAAGGAGTTTTTTGAA

C-3' (primer 2) (the residues at which mutations were introduced are underlined; e.g. for construction of the D1 mutant cDNA, in both primers 1 and 2 the first underlined A nucleotide was substituted by a C nucleotide). The PCR products were digested
30 with EcoRI and HindIII restriction enzymes and they were cloned into pT3NA_m1 cut with the same enzymes. NA genes and the flanking sequences in the modified plasmids were sequenced with an automated sequencer (Applied Biosystems).

The following double-mutations were introduced into the NA gene of influenza A/WSN/33 virus: U-A-G-C (10-11') (mutant D1), C-G-A-U (11-12') (mutant D2), and C-G-U-A (12-13') (mutant D3) (Fig. 1). In addition, six NA genes with the corresponding single-mutations were constructed (U-G10, A-C11', C-A11, G-U12', C-U12, and G-A13').

Example 2

Production of and transfection of ribonucleoprotein (RNP) complexes.

Transfectant viruses were prepared as described by Enami and Palese (5). NA-specific RNP complexes were reconstituted *in vitro* and transfected into MDBK cells infected with A/WSN-HK helper virus (5).

Synthetic RNAs were obtained by T3 RNA polymerase transcription of modified pT3NAM1 plasmids linearized with BbsI restriction enzyme. RNAs were reconstituted into RNP complexes using RNA polymerase and NP protein isolated from influenza X-31 virus. Influenza X-31 virus is a reassortant of influenza A/HK/8/68 and A/PR/8/34 viruses and was supplied by Evans Biological, Ltd., Liverpool, England. The RNP complexes were transfected by the DEAE-dextran transfection method into MDBK cells infected with WSN-HK helper influenza virus grown in 10-day embryonated chicken eggs. The MDBK cells were grown in reinforced minimal essential medium. For subsequent experiments, influenza A/WSN/33 wild-type virus was also grown in MDBK cells in reinforced minimal essential medium. Rescued transfectant viruses were plaque purified three times in MDBK cells. A single plaque was used for preparing a stock virus for further analysis.

Example 3

Sequencing of the NA genes of transfectant viruses.

The presence of the mutations in the transfectants was confirmed by sequence analysis of the 3' and 5' terminal sequences of the NA gene. Viral RNA for sequencing was isolated by phenol-chloroform extraction from transfectant viruses purified by centrifugation through a 30 % sucrose cushion. In some cases, total RNA isolated with RNazol B (Tel-Test, Inc., Friendswood, TX) from infected cells was used.

Sequences of the 5' end were obtained either by direct RNA sequencing or by 5' RACE. Direct sequencing of the 5' ends was performed using a primer complementary to nucleotide positions 1280 to 1299 (5'-TGGACTAGTGGGAGCATCAT-3') of the influenza A/WSN/33 NA gene and an RNA sequencing kit (United States Biochemical Corporation, Cleveland, OH) following the manufacturer's instructions. For 5' RACE, viral RNA was reverse transcribed using a primer complementary to nucleotide positions 879 to 898 (5'-GGGTGTCCTTCGACCAAAAC-3') of the influenza A/WSN/33 NA gene. The reverse transcription product was extended with terminal deoxynucleotidyl transferase (TdT) (Gibco BRL, Gaithersburg, MD) and amplified by PCR with the primer used for direct RNA sequencing (see above) and the 5' RACE abridged anchor primer (Gibco BRL). PCR products, cut with SpeI restriction enzyme, were cloned into the XbaI site of pUC18 and sequenced with a DNA sequencing kit (United States Biochemical). In order to sequence the 3' end of the NA gene of transfectant viruses, viral RNA was 3'-polyadenylated using poly(A) polymerase (Gibco BRL). The polyadenylated RNA was reverse transcribed using the primer 5'-GCGCAAGCTTCTAGATTTTTTTTTTTTTTTT-3' and the cDNA was amplified by PCR with a primer containing nucleotides corresponding to positions 115 to 98 (5'-GCGCAAGCTTTATTGAGATTATATTTC-3') of the influenza A/WSN/33 NA gene and the primer used for reverse transcription. PCR products digested with HindIII were cloned into pUC18 and sequenced with the DNA sequencing kit.

Transfection of all three NA genes with double-mutations resulted in rescue of transfectant viruses (D1, D2, and D3). On the other hand, only three out of the six single-mutant constructs were rescued, carrying mutations at positions 10, 11', and 13' (Fig. 1). In three attempts, none of the other three constructs (with mutations at positions 11, 12, and 12') was rescued.

Confirmation of mutations in the two single mutant transfectants at positions 10 and 11' was more difficult since they were unstable. Specifically, cloning of the 3' end of the NA vRNA of the U-G10 mutant resulted in one clone with mutant and two clones with wild-type sequences. Direct RNA sequencing of the 5' end of the NA-specific vRNA from purified A-C11' transfectant, following three plaque to plaque passages, revealed a wild-type sequence. However, when NA-specific vRNA

from MDBK cells infected with the original plaque of this transfectant was sequenced, the presence of the mutation was confirmed. Thus it seems likely that the transfectant reverted to wild-type during the plaque purification steps. This interpretation is supported by the observation that the transfectant initially produced small plaques, but showed larger plaques upon passaging. Taken together, sequencing data of the single mutants showed that transfectant viruses with single mutations, at least those with mutations at positions 10 and 11', are unstable.

Example 4

Growth properties of the D1, D2 D1/2 and D3 mutants

D1, D2, and D3 were grown on MDBK cells. Confluent monolayers of MDBK cells were infected at low m.o.i. (0.01) and the amount of infectious virus released into the medium was assayed at different time points by plaque assay on MDBK cells (Fig. 2). The D2 transfectant virus showed approximately one log reduction in plaque titre compared to the wild-type virus. However, D1 and D3 transfectant viruses were not significantly affected by the mutations. Consistently, the plaque size of D2 was reduced, but both D1 and D3 viruses showed plaque sizes similar to that of the wild-type.

The growth properties were also investigated of mutant influenza A/WSN/33 having multiple double-mutations in the NA-specific vRNA. A construct incorporating double-mutations from both D1 and D2 transfectants was successfully rescued (D1/2) (Fig. 1) into infectious virus. The D1/2 transfectant was plaque purified three times and the presence of mutations was confirmed by sequencing. This virus showed similar reduction in plaque titres (Fig. 2) and plaque size on MDBK cells as the D2 transfectant. The effect of the D1/2 mutations on viral growth was more dramatic on MDCK and Vero cells where reductions of at least three to four logs in plaque titres were observed (see Examples 10 and 11 below).

Example 5

Measurement of NA levels in transfectant viruses

The levels of NA expressed by the viruses was determined to see if it corresponded to growth levels. Influenza A/WSN/33 and transfectant viruses were

grown in MDBK cells and purified by 30 to 60% sucrose gradient ultracentrifugation. About 10 μg of viral proteins were denatured with 0.5% SDS and 1% β -mercaptoethanol at 100 °C for 10 minutes and digested with 400 u of PNGase F (New England Biolabs, Inc., Beverly, MA) for 20 h at 37 °C in a reaction buffer
5 containing 50 mM sodium phosphate, pH 7.5, 1% NP-40, and 5 mM Pefabloc (Boehringer Mannheim Corporation, Indianapolis, IN). The PNGase F treatment removes N-linked carbohydrate chains from NA and HA. This gives a better resolution of the NA band which migrates closely to NP and HA on gels. Proteins were analyzed by 12% SDS-PAGE and staining with Coomassie Brilliant Blue.

10 Both D2 and D1/2 virions showed a dramatic reduction in NA content compared to that of the wild-type virus or the D1 and D3 transfectants.

In order to quantitate NA levels of the D2 and D1/2 viruses, neuraminidase activity was measured. About 2 μg , 0.5 μg , 0.125 μg , and 0.031 μg (4 fold dilutions) of proteins from purified virus were incubated for 10 minutes at 37 °C in 150 mM
15 phosphate buffer, pH 6.0, 1 mM CaCl_2 , containing 50 nmols of 2'-(4-methylumbelliferyl)- α -D-N-acetylneuraminic acid (MU-NANA) as substrate in a total volume of 100 μl (27). Then 2 ml of stop buffer (0.5 M glycine/NaOH, pH 10.4) were added and the released 4-methylumbelliferone was determined by spectrofluorometry. 0.1 mM solution of 4-methylumbelliferone was used as a standard control. NA
20 activity was expressed as nmoles of 4-methylumbelliferone released in 1 minute per μg of viral proteins.

NA activity associated with the wild-type virus was 2.18 $\text{nmol min}^{-1} \mu\text{g}^{-1}$. However, the transfectant viruses D2 and D1/2 exhibited only 0.24 and 0.25 $\text{nmol min}^{-1} \mu\text{g}^{-1}$ activity, respectively. Thus, the transfectant viruses showed approximately
25 a 10 fold reduction in NA activity compared to the wild-type virus which is in agreement with the reduced NA levels observed in SDS-PAGE.

Example 6

NA-specific vRNA levels in purified transfectant viruses

30 Viral RNA from wild-type and transfectant viruses purified through a 30% sucrose cushion was extracted with phenol/chloroform. The viral RNAs purified from wild-type and transfectant viruses were analyzed by PAGE and the RNA segments

were visualized by silver-staining. The NA segment was present in all transfectant viruses at levels comparable to that of the wild-type virus. In order to quantify NA-specific vRNA levels, a primer extension analysis was performed using vRNA extracted from purified viruses.

5 Primer extension analysis of NA and NS vRNA levels was performed as previously described (2). Briefly, 100 ng of viral RNA was transcribed with 200 u of SuperScript (Gibco BRL) for 1 h at 42 °C in the presence of 3×10^5 cpm of ^{32}P -labelled NA- and NS-specific primers. The NA-specific primer, 5'-GTGGCAATAACTAATCGGTCA-3', is complementary to nucleotides 1151 to 1171
10 of the NA vRNA. The NS-specific primer, 5'-GGGAACAATTAGGTCAGAAGT-3', is complementary to positions 695 to 715 of the NS vRNA. Primer extension reactions were stopped by adding an equal volume of 90% formamide and 10 mM EDTA followed by heating to 95 °C for 3 minutes. Extension products were analyzed on 5% polyacrylamide gels in the
15 presence of 7 M urea and quantitated by phosphorimager analysis of dried gels (Molecular Dynamics).

 The NS gene was used as an internal control. The amounts of NA-specific vRNA segments in the transfectant viruses were similar ($\pm 20\%$) to that of the wild-type virus in two experiments.

20

Example 7

NA-specific vRNA levels in cells infected with the D2 or D1/2 transfectant viruses.

 MDBK cells were infected with wild-type or transfectant viruses at an m.o.i. of 2 and total RNA was isolated from cells at 3.0, 5.5, 8.0, and 10.5 h postinfection
25 with RNazol B (Tel-Test). NA-specific vRNA levels in total RNA were measured by primer extension assay as described above in example 6 using $5\mu\text{g}$ of total RNA. Cells infected with the D2 transfectant virus contained NA-specific vRNA levels similar ($\pm 10\%$) to those infected with the wild-type virus. Although cells infected with the D1/2 transfectant virus showed a 28 to 53% reduction in NA-specific vRNA
30 levels (results obtained by phosphorimager analysis in two experiments at 5.5, 8.0, and 10.5 h postinfection), this decrease cannot account for the ten-fold reduction of NA protein levels.

Example 8

NA-specific mRNA and cRNA levels in cells infected with the D2 or D1/2 transfectant viruses.

Since NA-specific vRNA levels were not dramatically affected by the mutations in the D2 and D1/2 transfectant viruses, the 10 fold reduction in NA levels (see above) could result from a reduction in mRNA levels and/or from a defect in translation. In order to distinguish between these possibilities, the amounts of NA-specific mRNA in cells infected with D2 or D1/2 transfectant viruses were measured by using a primer extension assay. MDBK cells were infected at an m.o.i of 2 with wild-type or transfectant viruses and total RNA was isolated at 3.0, 4.5, 6.0, and 7.5 h postinfection.

Primer extension analysis of NA and HA mRNA and cRNA levels in total RNA from infected cells was performed under the same conditions as described in example 6. The primer for NA-specific mRNA and cRNA, 5'-GCGCAAGCTTTATTGAGATTATATTTCC-3', contains 18 nucleotides (underlined) corresponding to positions 115 to 98 of the NA gene. The primer for the extension of HA-specific mRNA and cRNA, 5'-CATATTGTGTCTGCATCTGTAGCT-3', corresponds to positions 94 to 71 of the HA gene.

Since total RNA from infected cells contains both mRNA and cRNA, which differ only at their termini, signals for both species of RNAs were expected in the same primer extension assay. Due to the presence of a heterologous 10 to 15 nucleotides long capped primer at the 5' end of mRNA molecules, the signal for mRNA on gels appears as a multiple band containing DNA species of different sizes. On the other hand, the signal for cRNA appears as a single band, which is approximately 10 to 15 nucleotides shorter than the signal for mRNA.

NA-specific mRNA levels in cells infected with either D2 or D1/2 transfectant virus were below detection levels. NA-specific cRNA levels were apparently unaffected in these transfectant viruses. An additional band running slightly faster than the NA-specific cRNA band, detected in all samples, represents a nonspecific signal, since it was also detected in RNAs extracted from uninfected cells.

The observed attenuation of NA-specific mRNA levels in cells infected with

the D2 transfectant is consistent with the previous findings of Kim et al. (14) that an A-U(11-12') base-pair mutation in the context of a vRNA-like CAT reporter gene resulted only in 22% reporter activity compared to a wild-type control. However, the G-C(10-11') and U-A(12-13') base-pair mutations, which had no effect on the expression levels of the neuraminidase of the D1 and D3 transfectants, resulted in only 20 and 31% activities, respectively, in a CAT reporter gene system (14). It is thus clear that base-pair mutations in the context of a CAT reporter gene system and a rescued native NA gene containing vRNA segment have different effects.

10 Example 9

In vitro transcription of NA-specific ribonucleoprotein complexes.

In theory, the reduction of mRNA levels observed as above could have been caused by a decrease in mRNA stability or by a decrease in mRNA synthesis. The interference with mRNA synthesis may occur at the point of initiation, e.g. capped RNA primer binding or endonuclease activity could be inhibited. Alternatively, termination or polyadenylation of viral mRNA could be affected. In order to distinguish between all these possibilities, in vitro transcription assays were performed.

Wild-type influenza A/WSN/33 virus, D2, and D1/2 transfectants were grown in MDBK cells and purified on a 30% sucrose cushion. Twelve 15 cm dishes were used for each virus. The purified viruses were resuspended in 200 μ l of PBS and disrupted by adding 50 μ l of 5x disruption buffer (500 mM Tris-HCl [pH 7.4], 500 mM NaCl, 25 mM MgCl₂, 5 mM DTT, 25% glycerol, 2.5% NP-40, 2.5% Triton X-100, 50 mg ml⁻¹ lysolecithin) and incubation at 37 °C for 30 min. The disrupted viruses were fractionated by centrifugation on a discontinuous glycerol gradient (70%, 50%, and 30%, 150 μ l of each) in 100 mM Tris-HCl (pH 7.4), 100 mM NaCl, 5 mM MgCl₂, and 1 mM DTT. The gradients were centrifuged for 4 h at 15 °C in 0.8 ml tubes at 45,000 rpm in a Beckman SW55 rotor with adaptors. Fractions collected from the bottom of the tubes were analyzed by 12% SDS-PAGE and those enriched in RNPs were used in transcription assays.

In vitro transcriptional activity was measured using globin mRNA as primer. Transcription reactions were performed by using 6 μ l of RNPs in a total reaction

volume of 20 μ l containing 50 mM Tris-HCl (pH 7.8), 50 μ M KCl, 10 mM NaCl, 5 mM MgCl_2 , 5 mM DTT, 1 mM ATP, 0.5 mM each GTP and CTP, 50 μ M UTP, 0.1 μ M [α - ^{32}P] UTP (3,000 Ci mmol $^{-1}$), 20 u of RNase inhibitor (Boehringer Mannheim Corporation, Indianapolis, IN), 0.6 μ g of rabbit globin mRNA (Gibco BRL). After
5 incubation at 31 $^{\circ}\text{C}$ for 1.5 h, transcription products were extracted with phenol/chloroform and precipitated in the presence of 5 μ g of carrier yeast RNA.

NA-specific transcription products were synthesized from both the wild-type and the transfectant RNPs. However, there was a significant difference in the pattern of the bands. The wild-type NA-specific transcription product appeared as a wide
10 band corresponding to RNA species with poly(A) tails of different sizes. On the other hand, the NA-specific transcription products of both the D2 and D1/2 transfectants produced less diffuse bands, which implied that these products might not be polyadenylated. In order to characterize the transcription products, they were analyzed by oligo(dT)-cellulose chromatography.

15 The fractions depleted of poly(A)-containing molecules showed higher levels of NA-specific transcription products for the D2 and D1/2 transfectants, but lower levels for the wild-type control. On the other hand, fractions enriched in poly(A)-containing molecules showed lower levels of the NA-specific transcription products for the D2 and D1/2 transfectants, but higher levels for the wild-type virus. This
20 seems to confirm that there is a large proportion of NA-specific transcription products of the D2 and D1/2 transfectants which lack poly(A) tails.

It is thus proposed that the mutations in the NA-specific vRNA of D2 and D1/2 interfere with polyadenylation of mRNA transcripts. The observed low levels of
25 mRNA in cells infected with these viruses is fully consistent with this conclusion, since non-polyadenylated capped transcripts are most likely rapidly degraded in the cell (30).

Example 10

Growth of transfectant viruses on MDCK cells.

30 MDCK cells in 96-well plates were infected with 5×10^4 pfu and 10 times dilutions of wild-type influenza A/WSN/33 virus, or transfectant D1, D2, D3, and D1/2 viruses. Four wells were used for each virus. Infected cells were maintained in

100 μ l of Dulbecco's minimal essential medium (DMEM) supplemented with 10% bovine serum albumin and 1 μ g/ml of trypsin. After 72 h, 50 μ l of the medium was tested for hemagglutination with 50 μ l of 1.5% red blood cells and ID₅₀ was calculated for each virus. ID₅₀ is defined as the dose at which 50% of the medium of
5 the infected cells gives a positive haemagglutination signal. It was found that the ID₅₀ for the wild-type virus and the D1 transfectant was 5 pfu. On the other hand, the ID₅₀ of the D3 transfectant was 20 times higher. The ID₅₀ of the D2 and D1/2 transfectant was approximately 3000 times higher than that of the wild-type or the D1 transfectant.

10

Example 11

Growth of the D1/2 transfectant on Vero cells.

Confluent Vero cells in 35 mm dishes were infected at an m.o.i. of 0.01 with wild-type influenza A/WSN/33 virus or D1/2 transfectant in duplicates. Cells were
15 maintained in DMEM supplemented with 2% FBS for 72 h and virus present in the medium was titrated by plaque assay on MDBK cells. The wild-type virus reached 5×10^7 pfu/ml, but there was less than 5×10^2 pfu/ml of infectious virus in the medium from the cells infected with the D1/2 transfectant.

Taken together, the data in examples 4, 10 and 11 show that base-pair
20 mutations in the double-stranded region of the promoter of an influenza A virus vRNA can lead to reduced growth of influenza virus in tissue culture. As noted above, the D2 and D1/2 transfectant viruses showed approximately one log reduction in growth in MDBK cells, while both the D1 and D3 viruses grew like the wild-type. A more dramatic reduction in growth was observed for the D2 and D1/2 viruses on
25 MDCK and Vero cells. Interestingly, the D3 transfectant showed reduced growth on MDCK cells compared to the wild-type. Both D2 and D1/2 transfectants exhibited approximately four log reduction on MDCK cells, and the D1/2 transfectant 5 log reduction on Vero cells. Such results are indicative that influenza A viruses having the D2 and D1/2 mutations will exhibit effective attenuation *in vivo*.

30

Example 12

Passage of transfectant viruses and sequencing to determine the stability of the D1,

D2 and D3 mutations

Stocks of D1, D2, and D3 transfectant viruses with confirmed double-mutations were plaqued on MDBK cells and individual plaques were passaged ten times on MDBK cells at a low m.o.i. After ten passages, the viruses were plaqued and single plaques were used to prepare virus stocks for sequencing. Stocks of passaged viruses were purified through a 30 % sucrose cushion and viral RNA was isolated by phenol-chloroform extraction. In order to sequence the 3' end of the NA gene, viral RNA was 3'-polyadenylated using poly(A) polymerase (Gibco BRL, Gaithersburg, MD). The polyadenylated RNA was reverse transcribed using the primer 5'-GCGCAAGCTTCTAGATTTTTTTTTTTTTTTT-3' and the cDNA was amplified by PCR with a primer containing nucleotides corresponding to positions 115 to 98 (5'-GCGCAAGCTTTATTGAGATTATATTTC-3') of the influenza A/WSN/33 NA gene and the primer used for reverse transcription. PCR products digested with HindIII were cloned into pUC18 and sequenced with a DNA sequencing kit (United States Biochemical, Corporation, Cleveland, OH).

Three clones originating from three individually passaged plaques of the D1 transfectant showed the presence of the U-G10 mutation. All clones obtained from 5 individually passaged plaques of the D2 transfectant had the expected C-A11 mutation. In addition, two of the clones showed a U-C change at position 4 which is a natural variation observed among different influenza A virus isolates. In two of the clones, we have also found a U-C mutation at position 23 adjacent to the initiation codon for the neuraminidase which changes the second amino acid of NA from an asparagine to an aspartate. Only two of the clones obtained from the D3 transfectant showed the C-U12 mutation. The third clone had a wild-type sequence indicating that this base-pair mutation might not be stable. A reversion of A-G13' could result in a viable virus with a U-G(12-13') base-pair, which could then revert to the wild-type C-G(12-13') base-pair by a U-C12 change. Due to the presence of different residues such a reversion cannot occur at the other two studied base-pairs.

In summary, the mutations in the 3' end of D1 and D2 transfectants were preserved during ten passages. Preliminary data confirms the presence of the mutations also in the 5' end of the NA segment of the passaged transfectant viruses. It can be assumed that transfectant viruses with double-mutations should be stable

since two specific mutations would have to occur simultaneously in order to revert to the wild-type sequence. It did not prove possible to rescue any transfectant viruses with C→A11 or G→U12' single mutations which suggests that such viruses might be severely impaired or not viable at all.

5

Example 13

Use of the D1/2 transfectant virus as a helper virus to rescue NA genes

As noted above, the D1/2 transfectant virus showed approximately 5 log reduction in growth on Vero cells compared to wild-type influenza A/WSN/33. It can therefore be employed to provide an alternative rescue system for rescue of NA-encoding vRNA segments of influenza A viruses. An appropriate protocol for this consists of the following steps:

10

15

20

1. infection of MDBK cells with D1/2 helper virus;
2. treatment of the infected MDBK cells with DEAE-dextran/DMSO transfection reagent;
3. transfection of a synthetic NA ribonucleoprotein complex into D1/2 (or D2) helper virus infected and DEAE-dextran/DMSO-treated MDBK cells; and
4. selection of rescued viruses on Vero cells.

Only viruses which acquire the transfected NA gene grow to high titre on Vero cells.

REFERENCES

1. **Muster, T. Subbarao, E.K., Enami, M., Murphy, B.R. and Palese, P.** 1991. An influenza A virus containing influenza B virus 5' and 3' non-coding regions on the neuraminidase gene is attenuated in mice. *Proc. Natl. Acad. Sci. USA* 88, 5177-5181.
2. **Luo, G., Bergmann, M., García-Sastre, A., and Palese, P.** 1992. Mechanism of attenuation of a chimeric influenza A/B transfectant virus. *J. Virol.* 66, 4679-4685.
3. **Bergmann, M. and Muster, T.** 1995. The relative amount of an influenza A virus segment present in the viral particle is not affected by a reduction in replication of that segment. *J. Gen. Virol.* 76, 3211-3215
4. **Enami, M., W. Luytjes, M. Krystal, and P. Palese.** 1990. Introduction of site specific mutations into the genome of influenza virus. *Proc. Natl. Acad. Sci. USA* 87: 3802-3805.
5. **Enami, M., and P. Palese.** 1991. High-efficiency formation of influenza virus transfectants. *J. Virol.* 65: 2711-2713.
6. **Flick, R., G. Neumann, E. Hoffmann, E. Neumeier, and G. Hobom.** 1996. Promoter elements in the influenza vRNA terminal structure. *RNA* 2: 1046-1057.
7. **Fodor, E., D. C. Pritlove, and G. G. Brownlee.** 1994. The influenza virus panhandle is involved in the initiation of transcription. *J. Virol.* 68: 4092-4096.
8. **Fodor, E., D. C. Pritlove, and G. G. Brownlee.** 1995. Characterization of the RNA-fork model of virion RNA in the initiation of transcription in influenza A virus. *J. Virol.* 69: 4012-4019.

9. **García-Sastre, A., T. Muster, W. S. Barclay, N. Percy, and P. Palese.** 1994. Use of a mammalian internal ribosomal entry site element for expression of a foreign protein by a transfectant influenza virus. *J. Virol.* 68: 6254-6261.
10. **Gubareva, L. V., R. Bethell, G. J. Hart, K. G. Murti, C. R. Penn, and R. G. Webster.** 1996. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. *J. Virol.* 70: 1818-1827.
11. **Hagen, M., T. D. Y. Chung, J. A. Butcher, and M. Krystal.** 1994. Recombinant influenza virus polymerase: requirement of both 5' and 3' viral ends for endonuclease activity. *J. Virol.* 68: 1509-1515.
12. **Honda, A., and A. Ishihama.** 1997. The molecular anatomy of influenza virus RNA polymerase. *Biol. Chem.* 378: 483-488.
13. **Hsu, M., J. D. Parvin, S. Gupta, M. Krystal, and P. Palese.** 1987. Genomic RNAs of influenza viruses are held in a circular conformation in virions and in infected cells by a terminal panhandle. *Proc. Natl. Acad. Sci. USA* 84: 8140-8144.
14. **Kim, H-J., E. Fodor, G. G. Brownlee, and B. L. Seong.** 1997. Mutational analysis of the RNA-fork model of the influenza A virus vRNA promoter in vivo. *J. Gen. Virol.* 78: 353-357.
15. **Krug, R. M., F. V. Alonso-Caplen, I. Julkunen, and M. G. Katze.** 1989. Expression and replication of the influenza virus genome, p.98-152. In R. M. Krug (ed.), *The Influenza Viruses*. Plenum, New York.
16. **Li, X., and P. Palese.** 1992. Mutational analysis of the promoter required for influenza virus virion RNA synthesis. *J. Virol.* 66: 4331-4338.

17. **Li, X., and P. Palese.** 1994. Characterization of the polyadenylation signal of influenza virus RNA. *J. Virol.* 68: 1245-1249.
18. **Luo, G., W. Luytjes, M. Enami, and P. Palese.** 1991. The polyadenylation signal of influenza virus RNA involves a stretch of uridines followed by the RNA duplex of the panhandle structure. *J. Virol.* 65: 2861-2867.
19. **Luytjes, W., M. Krystal, M. Enami, J. D. Parvin, and P. Palese.** 1989. Amplification, expression, and packaging of a foreign gene by influenza virus. *Cell.* 59: 1107-1113.
20. **Martín, J., C. Albo, J. Ortín, J. A. Melero, and A. Portela.** 1992. In vitro reconstitution of active influenza virus nucleoprotein complexes using viral proteins purified from infected cells. *J. Gen. Virol.* 73: 1855-1859.
21. **Mena, I., S. de la Luna, C. Albo, J. Martín, A. Nieto, J. Ortín, and A. Portela.** 1994. Synthesis of biologically active influenza core proteins using a vaccinia-T7 RNA polymerase expression system. *J. Gen. Virol.* 75: 2109-2114.
22. **Neumann, G., and G. Hobom.** 1995. Mutational analysis of influenza virus promoter elements in vivo. *J. Gen. Virol.* 76: 1709-1717.
23. **O'Neill, R. E., J. Talon, and P. Palese.** 1998. The influenza virus NEP (NS2 protein) mediates the nuclear export of viral ribonucleoproteins. *EMBO J.* 17: 288-296.
24. **Palese, P.** 1977. The genes of influenza virus. *Cell* 10: 1-10.
25. **Parvin, J. D., P. Palese, A. Honda, A. Ishihama, and M. Krystal.** 1989. Promoter analysis of the influenza virus RNA polymerase. *J. Virol.* 63: 5142-5152.

26. **Piccone, M. E., A. Fernandez-Sesma, and P. Palese.** 1993. Mutational analysis of the influenza virus vRNA promoter. *Virus Res.* 28: 99-112.
27. **Potier, M., L. Mameli, M. Bélisle, L. Dallaire, and S. B. Melançon.** 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl- α -D-N-acetylneuraminate) substrate. *Anal. Biochem.* 94: 287-296.
28. **Pritlove, D. C., E. Fodor, B. L. Seong, and G. G. Brownlee.** 1995. In vitro transcription and polymerase binding studies of the termini of influenza A virus complementary RNA: evidence for a cRNA panhandle. *J. Gen. Virol.* 76: 2205-2213.
29. **Pritlove, D. C., L. L. M. Poon, E. Fodor, J. Sharps, and G. G. Brownlee.** 1998. Polyadenylation of influenza virus mRNA transcribed in vitro from model virion RNA templates: requirement for 5' conserved sequences. *J. Virol.* 72: 1280-1287.
30. **Proudfoot, N. J., and E. Whitelaw.** 1988. Termination and 3' end processing of eukaryotic RNA, p. 97-129. In D. M. Glover and B. D. Hames (ed.), *Frontiers in molecular biology – transcription and splicing*. IRL Press, Oxford.
31. **Robertson, J. S., M. Schubert, and R. A. Lazzarini.** 1981. Polyadenylation sites for influenza virus mRNA. *J. Virol.* 38: 157-163.
32. **Seong, B. L., and G. G. Brownlee.** 1992. A new method for reconstituting influenza polymerase and RNA in vitro: A study of the promoter elements for cRNA and vRNA synthesis in vitro and viral rescue in vivo. *Virology* 186: 247-260.
33. **Tiley, L. S., M. Hagen, J. T. Matthews, and M. Krystal.** 1994. Sequence-specific binding of the influenza virus RNA polymerase to sequences located at the 5' ends of the viral RNAs. *J. Virol.* 68: 5108-5116.

34. **Yamanaka, K., N. Ogasawara, H. Yoshikawa, A. Ishihama, and K. Nagata.** 1991. In vivo analysis of the promoter structure of the influenza genome using a transfection system with an engineered RNA. *Proc. Natl. Acad. Sci. USA* 88: 5369-5373.
35. **Zheng, H., P. Palese, and A. García-Sastre.** 1996. Nonconserved nucleotides at the 3' and 5' ends of an influenza A virus RNA play an important role in viral RNA replication. *Virology* 217: 242-251.
36. **Desselberger, U., Racariello, V.R., Zazra, J.J. and Palese, P.** 1980. The 3' and 5'-terminal sequences of influenza A, B and C virus RNA segments are highly conserved and show partial inverted complementarity. *Gene* 8, 315-328.
37. **Lee, Y-S and Seong, B.L.** 1996. Mutational Analysis of Influenza B virus RNA transcription in vitro. *J. Virol.* 70, 1232-1236.
38. **García-Sastre, A. and Palese, P.** 1993. Genetic manipulation of negative-strand RNA virus genomes. *Ann. Rev. Microbiol.* 47, 765-90.
39. **Li, S., Xu, M. and Coelingh, K.** 1995. Electroporation of ribonucleoprotein complexes for rescue of the nucleoprotein and matrix genes. *Virus Res.* 37, 153-161.
40. **Enami, M., Sharma, G., Benham, G. and Palese, P.** 1991. An influenza virus containing nine different RNA segments. *Virology* 185, 291-8.
41. **Subbarao, E. K., Park, E.J., Lawson, C.M., Chen, A.Y. and Murphy, B.R.** 1995. Sequential addition of temperature-sensitive missense mutations into the PB2 gene of influenza A transfectant virus can effect an increase in temperature sensitivity and attenuation and permits the rational design of a genetically engineered live influenza A virus vaccine. *J. Virol.* 69, 5969-77.

42. **Castrucci M. R. and Kawaoka, Y.** 1995. Reverse genetics system for generation of an influenza A virus mutant containing a deletion of the carboxyl-terminal residue of M2 protein. *J. Virol.* 69, 2725-8.
43. **Liu, C. and Air, G. M.** 1993. Selection and characterisation of a neuraminidase-minus mutant of influenza virus and its rescue by cloned neuraminidase genes. *Virology* 194, 403-7.
44. **Barclay, W.S. and Palese, P.** 1995. Influenza B viruses with site-specific mutations introduced into the NA gene. *J. Virol.* 76, 3211-5.
45. **Pleschka, S., Jaskmann, R., Engelhardt, O.G., Zurcher, T., Palese P. and García-Sastre, A.** 1996. A plasmid-based reverse genetics system for influenza A virus. *J. Virol.* 70, 4188-92.
46. **Enami, M.** 1997. Improved technique to genetically manipulate influenza virus. In *Frontiers of RNA Virus Research* p.19., The Oji International Seminar in Natural Science, Kyoto, Japan 1997.
47. Published International Application WO 91/03552 (Palese, P. et al.)
48. **Li, S., Polords, V., Isobe, H. et al.** 1993. Chimeric influenza virus induces neutralising antibodies and cytotoxic T cells against human immunodeficiency virus type 1. *J. Virol.* 67, 6659-66.
49. **Muster T., Ferko B., Klima, A. et al.** 1995. Mucosal model of immunisation against human immunodeficiency virus type 1 with a chimeric influenza virus. *J. Virol.* 69, 6678-86.

50. **Rodrigues, M., Li, S., Murata, K., Rodrigues D.** 1994. Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. *J. Immunol.* 153, 4636-48.
51. **Percy, N., Barclay, W. S., García-Sastre, A. and Palese, P.** 1994. Expression of a foreign protein by influenza A virus. *J. Virol* 68, 4486-92.
52. **Horimoto, T. and Kawaoka, Y.** 1994. Reverse genetics provides direct evidence for a correlation of haemagglutinin cleavability and virulence of an avian influenza A virus. *J. Virol.* 68, 3120-3128.
53. **Ferko, B., Egorav, A. et al.** 1997. Influenza virus as a vector for mucosal immunisation. In *Frontiers of RNA Virus Research*, p.18. The Oji International Seminar in Natural Science, Kyoto, Japan.
54. **Li et al.** 1993. Glycolysation of neuraminidase determines the neurovirulence of influenza A/WSN/33. *J. Virol.* 67, 6667-73.

CLAIMS

1. An attenuated influenza virus carrying a genomic nucleic acid segment which comprises 5' and 3' non-coding regions providing a mutated duplex region of an influenza virus RNA genomic segment operably-linked to a protein coding sequence for an influenza viral protein or a functional modification thereof, wherein said duplex region has at least one base-pair substitution such that expression of said protein-coding sequence in cells infected by said virus is reduced.
2. A virus as claimed in claim 1 which exhibits a reduction in plaque titre compared to the parent wild-type virus on cells of one or more type selected from Madin-Darby bovine kidney (MDBK) cells, Madin-Darby canine kidney (MDCK) cells and Vero cells.
3. A virus as claimed in claim 2 which exhibits at least about one log reduction in plaque titre compared to the parent wild type virus on MDBK cells.
4. A virus as claimed in claim 2 or claim 3 which exhibits at least about 3 to 4 log reduction in plaque titre compared to the parent wild type virus on MDCK cells and Vero cells.
5. A virus as claimed in any one of claims 1 to 4 wherein said nucleic acid is a mutated native influenza virus genomic RNA segment.
6. A virus as claimed in any one of claims 1 to 5 which is an attenuated influenza virus of type A, wherein said nucleic acid segment is a mutated influenza A virus genomic RNA segment having the mutation C to A at position 11 from the 3'-terminus and the mutation G to U at position 12' from the 5'-terminus, or functionally equivalent substitutions at the same positions, so as to provide an attenuating base-pair substitution in the non-coding duplex region.

7. A virus as claimed in claim 6 wherein said nucleic acid segment also has the mutation U to G at position 10 from the 3' terminus and the mutation A to C at position 11' from the 5' terminus, or functionally equivalent substitutions at the same positions, so as to provide an additional base-pair substitution in the non-coding duplex region.
8. A virus as claimed in claim 6 or claim 7 wherein said nucleic acid segment encodes neuraminidase (NA) or a functional modification thereof.
9. A virus as claimed in claim 1 which is an influenza virus of type B carrying a mutated influenza B virus genomic RNA segment having an attenuating base-pair substitution in the non-coding duplex region at a functionally homologous position to the base-pair substitution defined in claim 6.
10. A virus as claimed in claim 1 which is an influenza virus of type C carrying a mutated influenza C virus genomic RNA segment having an attenuating base-pair substitution in the non-coding duplex region at a functionally homologous position to the base-pair substitution defined in claim 6.
11. A virus as claimed in any one of claims 1 to 10 which is a wild-type virus which has been attenuated by said base-pair substitution(s).
12. A virus as claimed in any one of claims 1 to 10 which additionally comprises a heterologous coding sequence capable of being expressed in target cells.
13. A virus as claimed in claim 12 wherein said heterologous coding sequence encodes an antigenic polypeptide capable of stimulating an immune response to a pathogenic agent.
14. A virus as claimed in claim 11 which is attenuated influenza A/WSN/33 having a NA-encoding nucleic acid segment as defined in claim 8.

15. A nucleic acid as defined in claim 1 or any one of claims 5 to 10.
16. A DNA capable of transcription to provide a nucleic acid according to claim 15.
17. A plasmid containing a DNA as claimed in claim 16.
18. A ribonucleoprotein (RNP) complex wherein a nucleic acid as claimed in claim 15 is complexed with polymerase proteins and nucleoprotein of an influenza virus for use in preparing an attenuated virus as claimed in any one of claims 1 to 14.
19. An *ex vivo* cell infected by a virus as claimed in any one of claims 1 to 14.
20. A vaccine comprising a virus as claimed in any one of claims 1 to 13.
21. A pharmaceutical composition comprising a virus as claimed in claim 12 in combination with a pharmaceutically acceptable carrier or diluent for delivery of said heterologous coding sequence to target cells.
22. A pharmaceutical composition comprising cells infected with a virus according to claim 12 or claim 13 in combination with a pharmaceutically acceptable carrier or diluent.
23. A method of preparing a virus according to any one of claims 1 to 14 which comprises providing in a host cell the genomic nucleic acid segments for said virus under conditions whereby said segments are packaged into a viral particle.
24. Use of a virus as claimed in any one of claims 1 to 14 as a helper virus to rescue an influenza virus genomic nucleic acid segment in cells, wherein viruses produced containing said nucleic acid segment are selected on the

basis of increased growth compared with the helper virus on cells of a selected type.

25. Use of an influenza A virus as claimed in claim 8 as a helper virus in accordance with claim 24 to rescue an NA-encoding influenza A virus genomic nucleic acid segment or a functional modification thereof.
26. Use as claimed in claim 25 of attenuated influenza A/WSN/33 having mutations as defined in claim 7 in the NA-encoding genomic RNA segment, wherein selection of viruses carrying the nucleic acid segment to be rescued is carried out on Vero cells.


ABSTRACT

MODIFIED VIRUSES

An attenuated influenza virus carrying a genomic nucleic acid segment which comprises 5' and 3' non-coding regions providing a mutated duplex region of an influenza virus RNA genomic segment operably-linked to a protein coding sequence for an influenza viral protein or a functional modification thereof, wherein said duplex region has at least one base-pair substitution such that expression of said protein-coding sequence in cells infected by said virus is reduced. The attenuated influenza virus can be used in a vaccine.

5' AGUAGAAACA
3' UCGUUUUCG

11' 12' 13'
A G G
U C C
10 11 12



CG GC

AU AU GC

AU GC AU

CG UA UC

D1

D2


D3

D1/2

THIS PAGE BLANK (USPTO)

FIGURE 2

2/5



THIS PAGE BLANK (USPTO)

1 TCTTCCGCTT CCTCGCTCAC TGA CTCTGCTG CGCTCGGTCTG TTCGGCTGCG
51 GCGAGCGGTA TCAGCTCACT CAAAGGCGGT AATACGGTTA TCCACAGAAT
101 CAGGGGATAA CGCAGGAAAG AACATGTGAG CAAAAGGCCA GCAAAAGGCC
151 AGGAACCGTA AAAAGGCCGC GTTGCTGGCG TTTTCCATA GGCTCCGCCC
201 CCCTGACGAG CATCACAAAA ATCGACGCTC AAGTCAGAGG TGGCGAAACC
251 CGACAGGACT ATAAAGATAC CAGGCGTTTC CCCCTGGAAG CTCCCTCGTG
301 CGCTCTCCTG TTCCGACCCT GCCGCTTACC GGATACCTGT CCGCCTTTCT
351 CCCTTCGGGA AGCGTGCGC TTTCTCATAG CTCACGCTGT AGGTATCTCA
401 GTTCGGTGTA GGTCTGTCG TCCAAGCTGG GCTGTGTGCA CGAACCCCCC
451 GTTCAGCCCG ACCGCTGCGC CTTATCCGGT AACTATCGTC TTGAGTCCAA
501 CCCGGTAAGA CACGACTTAT CGCCACTGGC AGCAGCCACT GGTAACAGGA
551 TTAGCAGAGC GAGGTATGTA GCGGTGCTA CAGAGTTCTT GAAGTGGTGG
601 CCTAACTACG GCTACACTAG AAGGACAGTA TTTGGTATCT GCGCTCTGCT
651 GAAGCCAGTT ACCTTCGGAA AAAGAGTTGG TAGCTCTTGA TCCGGCAAAC
701 AAACCACCGC TGGTAGCGGT GGTTTTTTTG TTTGCAAGCA GCAGATTACG
751 CGCAGAAAAA AAGGATCTCA AGAAGATCCT TTGATCTTTT CTACGGGGTC
801 TGACGCTCAG TGGAACGAAA ACTCACGTTA AGGGATTTTG GTCATGAGAT
851 TATCAAAAAG GATCTTCACC TAGATCCTTT TAAATTAAAA ATGAAGTTTT
901 AAATCAATCT AAAGTATATA TGAGTAAACT TGGTCTGACA GTTACCAATG
951 CTTAATCAGT GAGGCACCTA TCTCAGCGAT CTGTCTATTT CGTTCATCCA
1001 TAGTTGCCTG ACTCCCCGTC GTGTAGATAA CTACGATACG GGAGGGCTTA
1051 CCATCTGGCC CCAGTGCTGC AATGATACCG CGAGACCCAC GCTCACCGGC
1101 TCCAGATTTA TCAGCAATAA ACCAGCCAGC CGGAAGGGCC GAGCGCAGAA
1151 GTGGTCCTGC AACTTTATCC GCCTCCATCC AGTCTATTAA TTGTTGCCGG
1201 GAAGCTAGAG TAAGTAGTTC GCCAGTTAAT AGTTTGCGCA ACGTTGTTGC
1251 CATTGCTACA GGCATCGTGG TGTCACGCTC GTCGTTTGGT ATGGCTTCAT
1301 TCAGCTCCGG TTCCCAACGA TCAAGGCGAG TTACATGATC CCCCATGTTG
1351 TGCAAAAAAG CGGTTAGCTC CTTCCGGTCCT CCGATCGTTG TCAGAAGTAA
1401 GTTGGCCGCA GTGTTATCAC TCATGGTTAT GGCAGCACTG CATAATTCTC
1451 TTA CTGT CAT GCCATCCGTA AGATGCTTTT CTGTGACTGG TGAGTACTCA
1501 ACCAAGTCAT TCTGAGAATA GTGTATGCGG CGACCGAGTT GCTCTTGCCC
1551 GGCGTCAATA CGGGATAATA CCGCGCCACA TAGCAGAACT TTAAAAGTGC

THIS PAGE BLANK (USPTO)

1601 TCATCATTGG AACGTTCT TCGGGGCGAA AACTCTCAA GATCTTACCG
 1651 CTGTTGAGAT CCAGTTCGAT GTAACCCACT CGTGACCCCA ACTGATCTTC
 1701 AGCATCTTTT ACTTTCACCA GCGTTTCTGG GTGAGCAAAA ACAGGAAGGC
 1751 AAAATGCCGC AAAAAAGGGA ATAAGGGCGA CACGGAAATG TTGAATACTC
 1801 ATACTCTTCC TTTTTC AATA TTATTGAAGC ATTTATCAGG GTTATTGTCT
 1851 CATGAGCGGA TACATATTTG AATGTATTTA GAAAAATAAA CAAATAGGGG
 1901 TTCCGCGCAC ATTTCCCCGA AAAGTGCCAC CTGACGTCTA AGAAACCATT
 1951 ATTATCATGA CATTAACTTA TAAAAATAGG CGTATCACGA GGCCCTTTTCG
 2001 TCTCGCGCGT TTCGGTGATG ACGGTGAAAA CCTCTGACAC ATGCAGCTCC
 2051 CGGAGACGGT CACAGCTTGT CTGTAAGCGG ATGCCGGGAG CAGACAAGCC
 2101 CGTCAGGGCG CGTCAGCGGG TGTGGCGGG TGTGGGGCT GGCTTAACTA
 2151 TGCGGCATCA GAGCAGATTG TACTGAGAGT GCACCATATG CGGTGTGAAA
 2201 TACCGCACAG ATGCGTAAGG AGAAAATACC GCATCAGGCG CCATTCGCCA
 2251 TTCAGGCTGC GCAACTGTTG GGAAGGGCGA TCGGTGCGGG CCTCTTCGCT
 2301 ATTACGCCAG CTGGCGAAAG GGGGATGTGC TGCAAGGCGA TTAAGTTGGG
 2351 TAACGCCAGG GTTTTCCCAG TCACGACGTT GTAAAACGAC GGCCAGTGAA
 2401 TTCGAAGACG CAGCAAAAGC AGGAGTTTAA ATGAATCCAA ACCAGAAAAT
 2451 AATAACCATT GGGTCAATCT GTATGGTAGT CGGAATAATT AGCCTAATAT
 2501 TGCAAATAGG AAATATAATC TCAATATGGA TTAGCCATTC AATTCAAACC
 2551 GGAAATCAAA ACCATACTGG AATATGCAAC CAAGGCAGCA TTACCTATAA
 2601 AGTTGTTGCT GGGCAGGACT CAACTTCAGT GATATTAACC GGCAATTCAT
 2651 CTCTTTGTCC CATCCGTGGG TGGGCTATAC ACAGCAAAGA CAATGGCATA
 2701 AGAATTGGTT CCAAAGGAGA CGTTTTTGTC ATAAGAGAGC CTTTTATTTC
 2751 ATGTTCTCAC TTGGAATGCA GGACCTTTTT TCTGACTCAA GGCGCCTTAC
 2801 TGAATGACAA GCATTCAAGG GGGACCTTTA AGGACAGAAG CCCTTATAGG
 2851 GCCTTAATGA GCTGCCCTGT CGGTGAAGCT CCGTCCCCGT ACAATTCAAG
 2901 GTTTGAATCG GTTGCTTGGT CAGCAAGTGC ATGTCATGAT GGAGTGGGCT
 2951 GGCTAACAAT CGGAATTTCT GGTCCAGATG ATGGAGCAGT GGCTGTATTA
 3001 AAATACAACC GCATAATAAC TGAAACCATA AAAAGTTGGA GGAAGAATAT
 3051 ATTGAGAACA CAAGAGTCTG AATGTACCTG TGTAATGGT TCATGTTTTA
 3101 CCATAATGAC CGATGGCCCA AGTGATGGGC TGGCCTCGTA CAAAATTTTC
 3151 AAGATCGAGA AGGGGAAGGT TACTAAATCA ATAGAGTTGA ATGCACCTAA
 3201 TTCTCACTAC GAGGAATGTT CCTGTTACCC TGATACCGGC AAAGTGATGT

THIS PAGE BLANK (USPTO)

3251 GTGTGTGCAG AGACAATTGG CACGGTTCGA ACCGACCA GGTGTCCTTC
3301 GACCAAAACC TAGATTATAA AATAGGATAC ATCTGCAGTG GGGTTTTTCGG
3351 TGACAACCCG CGTCCCAAAG ATGGAACAGG CAGCTGTGGC CCAGTGTCTG
3401 CTGATGGAGC AAACGGAGTA AAGGGATTTT CATATAAGTA TGGCAATGGT
3451 GTTTGGATAG GAAGGACTAA AAGTGACAGT TCCAGACATG GGTTCGAGAT
3501 GATTTGGGAT CCTAATGGAT GGACAGAGAC TGATAGTAGG TTCTCTATGA
3551 GACAAGATGT TGTGGCAATA ACTAATCGGT CAGGGTACAG CGGAAGTTTC
3601 GTTCAACATC CTGAGCTAAC AGGGCTAGAC TGTATGAGGC CTTGCTTCTG
3651 GGTTGAATTA ATCAGGGGGC TACCTGAGGA GGACGCAATC TGGACTAGTG
3701 GGAGCATCAT TTCTTTTGT GGTGTGAATA GTGATACTGT AGATTGGTCT
3751 TGGCCAGACG GTGCTGAGTT GCCGTCACC ATTGACAAGT AGTTTGTTCA
3801 AAAAATCCT TGTCTTACT TTTAGTGAGG GTTAATAAGC TTGGCGTAAT
3851 CATGGTCATA GCTGTTTCCT GTGTGAAATT GTTATCCGCT CACAATTCCA
3901 CACAACATAC GAGCCGGAAG CATAAAGTGT AAAGCCTGGG GTGCCTAATG
3951 AGTGAGCTAA CTCACATTAA TTGCGTTGCG CTCACTGCCC GCTTTCAGT
4001 CGGGAAACCT GTCGTGCCAG CTGCATTAAT GAATCGGCCA ACGCGCGGGG
4051 AGAGGCGGTT TGCCTATTGG GCGC

PCT | GB 99 | 01413

6.5.99

J A Kemp & Co

9809666.2

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference N.74383A JCI	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/GB 99/ 01413	International filing date (day/month/year) 06/05/1999	(Earliest) Priority Date (day/month/year) 06/05/1998
Applicant ISIS INNOVATION LIMITED et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☒ furnished subsequently to this Authority in written form.

☒ furnished subsequently to this Authority in computer readable form.

☒ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☒ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☐ the text is approved as submitted by the applicant.

☒ the text has been established by this Authority to read as follows:

ATTENUATED INFLUENZA VIRUSES

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☒ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

1
☐ None of the figures.

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 99/01413

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 26
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

International Application No

T/GB 99/01413

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/44 C12N7/01 C12N15/86 A61K39/145

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 704 533 A (HOBOM G ET AL.; BAYER AG) 3 April 1996 (1996-04-03) page 4, line 25 -page 5, line 35; figures 1,2 page 2, line 40 - line 49 ---	1-27
X	BERGMANN M AND MUSTER T: "The relative amount of influenza A virus segment present in the viral particle is not affected by a reduction in replication of that segment" JOURNAL OF GENERAL VIROLOGY, vol. 76, no. 12, December 1995 (1995-12), pages 3211-3215, XP002112523 READING GB cited in the application page 3214; figure 1 --- -/--	1-9, 13-26



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

15 October 1999

Date of mailing of the international search report

29/10/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Cupido, M

THIS PAGE BLANK (USPTO)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KIM H-J ET AL: "Mutational analysis of the RNA-fork model for the influenza A virus vRNA promoter in vivo" JOURNAL OF GENERAL VIROLOGY, vol. 78, no. 2, February 1997 (1997-02), pages 353-357, XP002112524 READING GB cited in the application figures 1,2 ---	1-9
X,P	FODOR E ET AL.: "Attenuation of influenza A virus mRNA levels by promoter mutations" JOURNAL OF VIROLOGY, vol. 72, no. 8, August 1998 (1998-08), pages 6283-6290, XP002112525 AMERICAN SOCIETY FOR MICROBIOLOGY US the whole document -----	1-17, 22-25

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 99/01413

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
EP 0704533	A	03-04-1996	AU	3607695 A	26-04-1996
			WO	9610641 A	11-04-1996
			EP	0783586 A	16-07-1997
			FI	971272 A	26-05-1997
			NZ	293600 A	28-01-1999

THIS PAGE BLANK (USPTO)